BBH Select Series – Mid Cap Fund Sold Bruker Corporation (BRKR) Due to Policy Uncertainty

Brown Brothers Harriman, an investment management company, released its Q3 2025 investor letter for the BBH Select Series – Mid Cap Fund. A copy of the same can be downloaded here. In the quarter, the fund decreased by -0.9% on a total return basis compared to the Russell Midcap Index’s 5.3% return. The Fund has decreased by a total return of -1.8%, YTD, compared to 10.4% for the Index. The third quarter experienced a boost in the low-quality rally that started late last year and gained momentum throughout 2025. For more information on the fund’s best picks in 2025, please check its top five holdings.

In its third-quarter 2025 investor letter, BBH Select Series – Mid Cap Fund highlighted stocks such as Bruker Corporation (NASDAQ:BRKR). Bruker Corporation (NASDAQ:BRKR) focuses on the development and manufacturing of scientific instruments and analytical and diagnostic solutions. The one-month return of Bruker Corporation (NASDAQ:BRKR) was 12.28%, and its shares lost 19.82% of their value over the last 52 weeks. On December 10, 2025, Bruker Corporation (NASDAQ:BRKR) stock closed at $46.92 per share, with a market capitalization of $7.129 billion.

BBH Select Series – Mid Cap Fund stated the following regarding Bruker Corporation (NASDAQ:BRKR) in its third quarter 2025 investor letter:

“The Fund’s largest detractors to performance in the quarter were Shift4 Payments Inc. (Shift4), Globant S.A. (Globant), and Bruker Corporation (NASDAQ:BRKR). We exited both Globant and Bruker during the quarter following sustained underperformance and to opportunistically harvest tax losses. These two companies have been our most impacted by tariffs and life science and academic funding cuts, and any re-entry would be predicated on a stabilization in performance.

Source link